Výsledky vyhledávání - "SORAFENIB"

Identification of ferroptosis-related genes as diagnostic biomarkers and therapeutic targets in sorafenib-resistant HCC via machine learning and experimental validation.

Autoři: Zhang J Geng W Sun H a další

Zdroj: International immunopharmacology [Int Immunopharmacol] 2025 Dec 03; Vol. 166, pp. 115557. Date of Electronic Publication: 2025 Sep 21.

Způsob vydávání: Journal Article

Informace o časopise: Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 100965259 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-1705 (Electronic) Linking ISSN: 15675769 NLM ISO Abbreviation: Int Immunopharmacol Subsets: MEDLINE

Výrazy ze slovníku MeSH: Ferroptosis*/genetics , Ferroptosis*/drug effects , Sorafenib*/therapeutic use , Sorafenib*/pharmacology , Carcinoma, Hepatocellular*/drug therapy , Carcinoma, Hepatocellular*/genetics , Carcinoma, Hepatocellular*/diagnosis , Drug Resistance, Neoplasm*/genetics , Liver Neoplasms*/drug therapy , Liver Neoplasms*/genetics , Liver Neoplasms*/diagnosis , Biomarkers, Tumor*/genetics , Antineoplastic Agents*/therapeutic use , Antineoplastic Agents*/pharmacology, Humans ; Machine Learning ; Autophagy-Related Protein-1 Homolog/genetics ; Cell Line, Tumor ; Kelch-Like ECH-Associated Protein 1/genetics ; Gene Expression Regulation, Neoplastic ; Coenzyme A Ligases/genetics ; Intracellular Signaling Peptides and Proteins

Cost-effectiveness analysis of anlotinib plus penpulimab versus sorafenib in the treatment of unresectable hepatocellular carcinoma.

Autoři: Luo J Li Z Gui C a další

Zdroj: Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2025 Dec; Vol. 21 (1), pp. 2582294. Date of Electronic Publication: 2025 Dec 01.

Způsob vydávání: Journal Article; Comparative Study

Informace o časopise: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101572652 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2164-554X (Electronic) Linking ISSN: 21645515 NLM ISO Abbreviation: Hum Vaccin Immunother Subsets: MEDLINE

Výrazy ze slovníku MeSH: Carcinoma, Hepatocellular*/drug therapy , Carcinoma, Hepatocellular*/economics , Cost-Benefit Analysis* , Sorafenib*/economics , Sorafenib*/therapeutic use , Sorafenib*/administration & dosage , Liver Neoplasms*/drug therapy , Liver Neoplasms*/economics , Quinolines*/economics , Quinolines*/therapeutic use , Quinolines*/administration & dosage , Indoles*/economics , Indoles*/therapeutic use , Indoles*/administration & dosage , Antineoplastic Agents*/economics , Antineoplastic Agents*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/economics , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use, Humans ; Quality-Adjusted Life Years ; China ; Male ; Cost-Effectiveness Analysis ; Antibodies, Monoclonal, Humanized

1,2,3-Triazole-modified sorafenib derivatives induce DNA damage, apoptosis, and PI3K/AKT pathway suppression in hepatocellular carcinoma: Design, synthesis, and evaluation.

Autoři: Mao L Wu J Wang Y a další

Zdroj: Bioorganic chemistry [Bioorg Chem] 2025 Dec; Vol. 167, pp. 109210. Date of Electronic Publication: 2025 Nov 07.

Způsob vydávání: Journal Article

Informace o časopise: Publisher: Elsevier Country of Publication: United States NLM ID: 1303703 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1090-2120 (Electronic) Linking ISSN: 00452068 NLM ISO Abbreviation: Bioorg Chem Subsets: MEDLINE

Výrazy ze slovníku MeSH: DNA Damage*/drug effects , Triazoles*/chemistry , Triazoles*/pharmacology , Triazoles*/chemical synthesis , Apoptosis*/drug effects , Carcinoma, Hepatocellular*/drug therapy , Carcinoma, Hepatocellular*/pathology , Carcinoma, Hepatocellular*/metabolism , Antineoplastic Agents*/pharmacology , Antineoplastic Agents*/chemical synthesis , Antineoplastic Agents*/chemistry , Liver Neoplasms*/drug therapy , Liver Neoplasms*/pathology , Liver Neoplasms*/metabolism , Sorafenib*/pharmacology , Sorafenib*/chemistry , Sorafenib*/chemical synthesis , Drug Design*, Humans ; Proto-Oncogene Proteins c-akt/metabolism ; Proto-Oncogene Proteins c-akt/antagonists & inhibitors ; Animals ; Phosphatidylinositol 3-Kinases/metabolism ; Mice ; Cell Proliferation/drug effects ; Drug Screening Assays, Antitumor ; Molecular Structure ; Structure-Activity Relationship ; Dose-Response Relationship, Drug ; Hep G2 Cells ; Signal Transduction/drug effects ; Mice, Nude

Targeting MED8 enhances sorafenib sensitivity in hepatocellular carcinoma by disrupting epithelial-mesenchymal transition mechanisms.

Autoři: Li M You X Yuan T a další

Zdroj: Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2025 Dec; Vol. 40 (1), pp. 2574988. Date of Electronic Publication: 2025 Oct 21.

Způsob vydávání: Journal Article

Informace o časopise: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101150203 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1475-6374 (Electronic) Linking ISSN: 14756366 NLM ISO Abbreviation: J Enzyme Inhib Med Chem Subsets: MEDLINE

Výrazy ze slovníku MeSH: Sorafenib*/pharmacology , Sorafenib*/chemistry , Epithelial-Mesenchymal Transition*/drug effects , Carcinoma, Hepatocellular*/drug therapy , Carcinoma, Hepatocellular*/metabolism , Carcinoma, Hepatocellular*/pathology , Liver Neoplasms*/drug therapy , Liver Neoplasms*/pathology , Liver Neoplasms*/metabolism , Antineoplastic Agents*/pharmacology , Antineoplastic Agents*/chemistry , Antineoplastic Agents*/chemical synthesis , Mediator Complex*/metabolism , Mediator Complex*/antagonists & inhibitors , Mediator Complex*/genetics, Humans ; Cell Proliferation/drug effects ; Drug Screening Assays, Antitumor ; Dose-Response Relationship, Drug ; Structure-Activity Relationship ; Apoptosis/drug effects ; Molecular Structure ; Tumor Cells, Cultured ; Cell Line, Tumor ; Drug Resistance, Neoplasm/drug effects

Berberine sensitizes liver cancer cells to sorafenib by inducing SETDB1/NQO1/p53-dependent ferroptosis and genomic instability.

Autoři: Li K Yi X Yu Z a další

Zdroj: European journal of pharmacology [Eur J Pharmacol] 2025 Nov 15; Vol. 1007, pp. 178211. Date of Electronic Publication: 2025 Oct 11.

Způsob vydávání: Journal Article

Informace o časopise: Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 1254354 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0712 (Electronic) Linking ISSN: 00142999 NLM ISO Abbreviation: Eur J Pharmacol Subsets: MEDLINE

Výrazy ze slovníku MeSH: Berberine*/pharmacology , Sorafenib*/pharmacology , Sorafenib*/therapeutic use , Liver Neoplasms*/pathology , Liver Neoplasms*/drug therapy , Liver Neoplasms*/genetics , Liver Neoplasms*/metabolism , Ferroptosis*/drug effects , Tumor Suppressor Protein p53*/metabolism , Genomic Instability*/drug effects , Carcinoma, Hepatocellular*/drug therapy , Carcinoma, Hepatocellular*/pathology , Carcinoma, Hepatocellular*/genetics , Antineoplastic Agents*/pharmacology, Humans ; Animals ; Mice ; Drug Synergism ; Hep G2 Cells ; Cell Proliferation/drug effects ; Cell Line, Tumor ; Xenograft Model Antitumor Assays ; Male ; Reactive Oxygen Species/metabolism

The role of solute carrier family 16 member 3 protein in hepatocellular carcinoma and sorafenib resistance.

Autoři: Peng X He Z Yuan D a další

Zdroj: International journal of biological macromolecules [Int J Biol Macromol] 2025 Nov; Vol. 330 (Pt 3), pp. 148223. Date of Electronic Publication: 2025 Oct 09.

Způsob vydávání: Journal Article

Informace o časopise: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 7909578 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0003 (Electronic) Linking ISSN: 01418130 NLM ISO Abbreviation: Int J Biol Macromol Subsets: MEDLINE

Výrazy ze slovníku MeSH: Sorafenib*/pharmacology , Sorafenib*/therapeutic use , Carcinoma, Hepatocellular*/drug therapy , Carcinoma, Hepatocellular*/genetics , Carcinoma, Hepatocellular*/metabolism , Carcinoma, Hepatocellular*/pathology , Liver Neoplasms*/drug therapy , Liver Neoplasms*/genetics , Liver Neoplasms*/metabolism , Liver Neoplasms*/pathology , Drug Resistance, Neoplasm*/genetics , Drug Resistance, Neoplasm*/drug effects , Monocarboxylic Acid Transporters*/genetics , Monocarboxylic Acid Transporters*/metabolism, Humans ; Animals ; Gene Expression Regulation, Neoplastic/drug effects ; Tumor Microenvironment/drug effects ; Mice ; Cell Line, Tumor

Enhanced anti-cancer efficacy of Sorafenib and Pioglitazone via VEGF inhibition in DMBA-induced breast cancer model.

Autoři: Soni K Shah J

Zdroj: Toxicology mechanisms and methods [Toxicol Mech Methods] 2025 Nov; Vol. 35 (9), pp. 1354-1373. Date of Electronic Publication: 2025 Jul 28.

Způsob vydávání: Journal Article

Informace o časopise: Publisher: Informa Healthcare Country of Publication: England NLM ID: 101134521 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1537-6524 (Electronic) Linking ISSN: 15376516 NLM ISO Abbreviation: Toxicol Mech Methods Subsets: MEDLINE

Výrazy ze slovníku MeSH: Sorafenib*/pharmacology , Sorafenib*/administration & dosage , Pioglitazone*/pharmacology , Pioglitazone*/administration & dosage , Mammary Neoplasms, Experimental*/chemically induced , Mammary Neoplasms, Experimental*/drug therapy , Mammary Neoplasms, Experimental*/pathology , Mammary Neoplasms, Experimental*/metabolism , Vascular Endothelial Growth Factor A*/antagonists & inhibitors , Vascular Endothelial Growth Factor A*/metabolism , Antineoplastic Combined Chemotherapy Protocols*/pharmacology , Antineoplastic Agents*/pharmacology , Breast Neoplasms*/drug therapy , Breast Neoplasms*/chemically induced , Breast Neoplasms*/pathology, Animals ; Female ; Rats, Sprague-Dawley ; 9,10-Dimethyl-1,2-benzanthracene/toxicity ; Humans ; MCF-7 Cells ; Oxidative Stress/drug effects ; Molecular Docking Simulation ; Rats

Senescence‑associated IL‑33 secretion undermines sorafenib efficacy in hepatocellular carcinoma via immune evasion.

Autoři: Lin YX Liu H Liao WC a další

Zdroj: Oncology reports [Oncol Rep] 2025 Nov; Vol. 54 (5). Date of Electronic Publication: 2025 Sep 19.

Způsob vydávání: Journal Article

Informace o časopise: Publisher: D.A. Spandidos Country of Publication: Greece NLM ID: 9422756 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1791-2431 (Electronic) Linking ISSN: 1021335X NLM ISO Abbreviation: Oncol Rep Subsets: MEDLINE

Výrazy ze slovníku MeSH: Sorafenib*/pharmacology , Sorafenib*/therapeutic use , Carcinoma, Hepatocellular*/drug therapy , Carcinoma, Hepatocellular*/immunology , Carcinoma, Hepatocellular*/pathology , Liver Neoplasms*/drug therapy , Liver Neoplasms*/immunology , Liver Neoplasms*/pathology , Interleukin-33*/metabolism , Interleukin-33*/antagonists & inhibitors , Drug Resistance, Neoplasm*/immunology , Drug Resistance, Neoplasm*/drug effects, Humans ; Animals ; Mice ; Xenograft Model Antitumor Assays ; B7-H1 Antigen/metabolism ; Cell Line, Tumor ; Cellular Senescence/drug effects ; Cellular Senescence/immunology ; Phenylurea Compounds/pharmacology ; Pyridines/pharmacology ; Signal Transduction/drug effects ; Male ; Gene Expression Regulation, Neoplastic/drug effects ; Cell Proliferation/drug effects

Hypoxia-induced HIF1A impairs sorafenib sensitivity in hepatocellular carcinoma through NSUN2-mediated stabilization of GDF15.

Autoři: Wang L Zhuang B Jiang Y a další

Zdroj: Cellular signalling [Cell Signal] 2025 Nov; Vol. 135, pp. 112076. Date of Electronic Publication: 2025 Aug 19.

Způsob vydávání: Journal Article

Informace o časopise: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 8904683 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-3913 (Electronic) Linking ISSN: 08986568 NLM ISO Abbreviation: Cell Signal Subsets: MEDLINE

Výrazy ze slovníku MeSH: Sorafenib*/pharmacology , Sorafenib*/therapeutic use , Carcinoma, Hepatocellular*/drug therapy , Carcinoma, Hepatocellular*/metabolism , Carcinoma, Hepatocellular*/pathology , Carcinoma, Hepatocellular*/genetics , Liver Neoplasms*/drug therapy , Liver Neoplasms*/metabolism , Liver Neoplasms*/pathology , Liver Neoplasms*/genetics , Growth Differentiation Factor 15*/metabolism , Growth Differentiation Factor 15*/genetics , Hypoxia-Inducible Factor 1, alpha Subunit*/metabolism, Humans ; Cell Line, Tumor ; Animals ; Mice ; Apoptosis/drug effects ; Drug Resistance, Neoplasm/drug effects ; Mice, Nude ; Gene Expression Regulation, Neoplastic/drug effects ; Cell Hypoxia ; Antineoplastic Agents/pharmacology

Cytotoxic Effects of Sorafenib, Lapatinib, and Bevacizumab, Alone and in Combination, on Medullary Thyroid Carcinoma Cells.

Autoři: Altun G Yönem Ö

Zdroj: Current oncology (Toronto, Ont.) [Curr Oncol] 2025 Oct 31; Vol. 32 (11). Date of Electronic Publication: 2025 Oct 31.

Způsob vydávání: Journal Article

Informace o časopise: Publisher: MDPI Country of Publication: Switzerland NLM ID: 9502503 Publication Model: Electronic Cited Medium: Internet ISSN: 1718-7729 (Electronic) Linking ISSN: 11980052 NLM ISO Abbreviation: Curr Oncol Subsets: MEDLINE

Výrazy ze slovníku MeSH: Bevacizumab*/pharmacology , Bevacizumab*/therapeutic use , Sorafenib*/pharmacology , Sorafenib*/therapeutic use , Carcinoma, Neuroendocrine*/drug therapy , Carcinoma, Neuroendocrine*/pathology , Thyroid Neoplasms*/drug therapy , Thyroid Neoplasms*/pathology , Lapatinib*/pharmacology , Lapatinib*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/pharmacology , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use, Humans ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Apoptosis/drug effects ; Cell Survival/drug effects ; Antineoplastic Agents/pharmacology

SCR Disease Name: Thyroid cancer, medullary

Study on the Mechanism of CCN2 Promoting Sorafenib Resistance in HCC and Its Combined Intervention Strategy.

Autoři: Cui L Liu J Lv Y a další

Zdroj: Frontiers in bioscience (Landmark edition) [Front Biosci (Landmark Ed)] 2025 Oct 31; Vol. 30 (10), pp. 45454.

Způsob vydávání: Journal Article

Informace o časopise: Publisher: IMR Press Country of Publication: Singapore NLM ID: 101612996 Publication Model: Print Cited Medium: Internet ISSN: 2768-6698 (Electronic) Linking ISSN: 27686698 NLM ISO Abbreviation: Front Biosci (Landmark Ed) Subsets: MEDLINE

Výrazy ze slovníku MeSH: Sorafenib*/pharmacology , Sorafenib*/therapeutic use , Connective Tissue Growth Factor*/metabolism , Connective Tissue Growth Factor*/genetics , Drug Resistance, Neoplasm*/genetics , Liver Neoplasms*/drug therapy , Liver Neoplasms*/pathology , Liver Neoplasms*/metabolism , Liver Neoplasms*/genetics , Carcinoma, Hepatocellular*/drug therapy , Carcinoma, Hepatocellular*/pathology , Carcinoma, Hepatocellular*/metabolism , Carcinoma, Hepatocellular*/genetics , Antineoplastic Agents*/pharmacology , Antineoplastic Agents*/therapeutic use, Humans ; Animals ; Mice ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Signal Transduction/drug effects ; Male ; Female ; Gene Expression Regulation, Neoplastic/drug effects ; Xenograft Model Antitumor Assays ; Mice, Nude ; Proto-Oncogene Proteins c-met/metabolism ; Middle Aged ; YAP-Signaling Proteins

Disrupting CARMA3 Signaling with Triptolide Reverses Sorafenib Resistance in Hepatocellular Carcinoma.

Autoři: Wang WY Hsu TW Su YH a další

Zdroj: International journal of medical sciences [Int J Med Sci] 2025 Oct 20; Vol. 22 (16), pp. 4353-4364. Date of Electronic Publication: 2025 Oct 20 (Print Publication: 2025).

Způsob vydávání: Journal Article

Informace o časopise: Publisher: Ivyspring International Publisher Country of Publication: Australia NLM ID: 101213954 Publication Model: eCollection Cited Medium: Internet ISSN: 1449-1907 (Electronic) Linking ISSN: 14491907 NLM ISO Abbreviation: Int J Med Sci Subsets: MEDLINE

Výrazy ze slovníku MeSH: Phenanthrenes*/pharmacology , Phenanthrenes*/therapeutic use , Diterpenes*/pharmacology , Diterpenes*/therapeutic use , Carcinoma, Hepatocellular*/drug therapy , Carcinoma, Hepatocellular*/pathology , Carcinoma, Hepatocellular*/genetics , Liver Neoplasms*/drug therapy , Liver Neoplasms*/pathology , Liver Neoplasms*/genetics , Drug Resistance, Neoplasm*/drug effects , Drug Resistance, Neoplasm*/genetics , Sorafenib*/pharmacology , Sorafenib*/therapeutic use, Humans ; Epoxy Compounds/pharmacology ; Epoxy Compounds/therapeutic use ; Signal Transduction/drug effects ; Reactive Oxygen Species/metabolism ; Cell Line, Tumor ; Xenograft Model Antitumor Assays ; Gene Expression Regulation, Neoplastic/drug effects ; Animals ; Mice

Lipid-Extruded PEGylated Liposomes of Repurposed Sorafenib for Triple-Negative Breast Cancer: A Mechanistically Enhanced Nanoplatform with Improved In Vivo Pharmacokinetics and Targeted Biodistribution.

Autoři: Pawar A Pardhi E Mehra NK

Zdroj: ACS applied bio materials [ACS Appl Bio Mater] 2025 Oct 20; Vol. 8 (10), pp. 8959-8979. Date of Electronic Publication: 2025 Sep 30.

Způsob vydávání: Journal Article

Informace o časopise: Publisher: ACS Publications Country of Publication: United States NLM ID: 101729147 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2576-6422 (Electronic) Linking ISSN: 25766422 NLM ISO Abbreviation: ACS Appl Bio Mater Subsets: MEDLINE

Výrazy ze slovníku MeSH: Triple Negative Breast Neoplasms*/drug therapy , Triple Negative Breast Neoplasms*/pathology , Triple Negative Breast Neoplasms*/metabolism , Sorafenib*/chemistry , Sorafenib*/pharmacokinetics , Sorafenib*/pharmacology , Antineoplastic Agents*/chemistry , Antineoplastic Agents*/pharmacology , Antineoplastic Agents*/pharmacokinetics, Liposomes/chemistry ; Polyethylene Glycols/chemistry ; Humans ; Tissue Distribution ; Animals ; Particle Size ; Mice ; Female ; Drug Screening Assays, Antitumor ; Cell Proliferation/drug effects ; Materials Testing ; Lipids/chemistry ; Cell Line, Tumor ; Cell Survival/drug effects ; Nanoparticles/chemistry ; Surface Properties

First-line immune checkpoint inhibitors plus targeted therapy versus sorafenib or lenvatinib monotherapy for unresectable or advanced hepatocellular carcinoma: a meta-analysis of phase 3 trials.

Autoři: Lin Y Liao Y Luo B a další

Zdroj: Frontiers in immunology [Front Immunol] 2025 Oct 15; Vol. 16, pp. 1667793. Date of Electronic Publication: 2025 Oct 15 (Print Publication: 2025).

Způsob vydávání: Journal Article; Meta-Analysis; Systematic Review; Comparative Study

Informace o časopise: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE

Výrazy ze slovníku MeSH: Carcinoma, Hepatocellular*/drug therapy , Carcinoma, Hepatocellular*/mortality , Carcinoma, Hepatocellular*/pathology , Immune Checkpoint Inhibitors*/therapeutic use , Immune Checkpoint Inhibitors*/adverse effects , Immune Checkpoint Inhibitors*/administration & dosage , Liver Neoplasms*/drug therapy , Liver Neoplasms*/mortality , Phenylurea Compounds*/therapeutic use , Phenylurea Compounds*/adverse effects , Sorafenib*/therapeutic use , Sorafenib*/adverse effects , Quinolines*/therapeutic use , Quinolines*/adverse effects , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects, Humans ; Clinical Trials, Phase III as Topic ; Molecular Targeted Therapy ; Treatment Outcome

SLC25A39 regulates Hedgehog signaling to promote tumor progression and sorafenib resistance in hepatocellular carcinoma.

Autoři: Qiu Q Yin H Zhang L a další

Zdroj: Scientific reports [Sci Rep] 2025 Oct 15; Vol. 15 (1), pp. 36061. Date of Electronic Publication: 2025 Oct 15.

Způsob vydávání: Journal Article

Informace o časopise: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

Výrazy ze slovníku MeSH: Sorafenib*/pharmacology , Sorafenib*/therapeutic use , Carcinoma, Hepatocellular*/drug therapy , Carcinoma, Hepatocellular*/pathology , Carcinoma, Hepatocellular*/metabolism , Carcinoma, Hepatocellular*/genetics , Liver Neoplasms*/drug therapy , Liver Neoplasms*/pathology , Liver Neoplasms*/metabolism , Liver Neoplasms*/genetics , Drug Resistance, Neoplasm*/genetics , Hedgehog Proteins*/metabolism , Signal Transduction*/drug effects, Humans ; Animals ; Mice ; Cell Line, Tumor ; Disease Progression ; Gene Expression Regulation, Neoplastic/drug effects ; Antineoplastic Agents/pharmacology ; Neoplastic Stem Cells/metabolism ; Neoplastic Stem Cells/drug effects ; Xenograft Model Antitumor Assays

TTC36-Mediated Tumor Suppression via YBX3/SPRED1 Axis Paradoxically Reduces Sorafenib Sensitivity in Hepatocellular Carcinoma.

Autoři: Zhao W Ling X Li K a další

Zdroj: International journal of biological sciences [Int J Biol Sci] 2025 Oct 01; Vol. 21 (14), pp. 6351-6372. Date of Electronic Publication: 2025 Oct 01 (Print Publication: 2025).

Způsob vydávání: Journal Article

Informace o časopise: Publisher: Ivyspring International Country of Publication: Australia NLM ID: 101235568 Publication Model: eCollection Cited Medium: Internet ISSN: 1449-2288 (Electronic) Linking ISSN: 14492288 NLM ISO Abbreviation: Int J Biol Sci Subsets: MEDLINE

Výrazy ze slovníku MeSH: Carcinoma, Hepatocellular*/metabolism , Carcinoma, Hepatocellular*/drug therapy , Carcinoma, Hepatocellular*/genetics , Sorafenib*/pharmacology , Sorafenib*/therapeutic use , Liver Neoplasms*/metabolism , Liver Neoplasms*/drug therapy , Liver Neoplasms*/genetics, Humans ; Animals ; Mice ; Cell Line, Tumor ; Cell Proliferation ; Male ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Gene Expression Regulation, Neoplastic ; Female ; Mice, Nude ; Mice, Inbred BALB C

Unveiling EFNB2 as a Key Player in Sorafenib Resistance: Insights from Bioinformatics Analysis and Functional Validation in Hepatocellular Carcinoma.

Autoři: Pan J Li Q Zhu J

Zdroj: Biochemical genetics [Biochem Genet] 2025 Oct; Vol. 63 (5), pp. 3825-3844. Date of Electronic Publication: 2024 Aug 30.

Způsob vydávání: Journal Article

Informace o časopise: Publisher: Kluwer Academic/Plenum Publishers Country of Publication: United States NLM ID: 0126611 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-4927 (Electronic) Linking ISSN: 00062928 NLM ISO Abbreviation: Biochem Genet Subsets: MEDLINE

Výrazy ze slovníku MeSH: Sorafenib*/pharmacology , Sorafenib*/therapeutic use , Carcinoma, Hepatocellular*/genetics , Carcinoma, Hepatocellular*/drug therapy , Carcinoma, Hepatocellular*/metabolism , Carcinoma, Hepatocellular*/pathology , Liver Neoplasms*/genetics , Liver Neoplasms*/drug therapy , Liver Neoplasms*/metabolism , Liver Neoplasms*/pathology , Drug Resistance, Neoplasm*/genetics, Humans ; Computational Biology/methods ; Gene Expression Regulation, Neoplastic ; Cell Line, Tumor ; Antineoplastic Agents/pharmacology ; Hep G2 Cells

A Phototherapy Nanosensitizer-Unlocked Multihit Strategy to Inhibit Tumor Stemness and Potentiate Sorafenib Response in Hepatocellular Carcinoma.

Autoři: Qin T Lu H Wang Q a další

Zdroj: ACS applied materials & interfaces [ACS Appl Mater Interfaces] 2025 Oct 01; Vol. 17 (39), pp. 54537-54552. Date of Electronic Publication: 2025 Sep 22.

Způsob vydávání: Journal Article

Informace o časopise: Publisher: American Chemical Society Country of Publication: United States NLM ID: 101504991 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1944-8252 (Electronic) Linking ISSN: 19448244 NLM ISO Abbreviation: ACS Appl Mater Interfaces Subsets: MEDLINE

Výrazy ze slovníku MeSH: Sorafenib*/pharmacology , Sorafenib*/chemistry , Sorafenib*/therapeutic use , Carcinoma, Hepatocellular*/drug therapy , Carcinoma, Hepatocellular*/pathology , Carcinoma, Hepatocellular*/metabolism , Liver Neoplasms*/drug therapy , Liver Neoplasms*/pathology , Liver Neoplasms*/metabolism , Neoplastic Stem Cells*/drug effects , Neoplastic Stem Cells*/pathology , Antineoplastic Agents*/pharmacology , Antineoplastic Agents*/chemistry , Antineoplastic Agents*/therapeutic use , Phototherapy* , Photosensitizing Agents*/chemistry , Photosensitizing Agents*/pharmacology, Humans ; Mice ; Animals ; Cell Line, Tumor ; Photochemotherapy ; Phosphorus/chemistry ; Phosphorus/pharmacology ; Mice, Inbred BALB C

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study.

Autoři: Qin S Gu S Chan SL a další

Korporace: Qin S Gu S Chan SL a další

Zdroj: The Lancet. Oncology [Lancet Oncol] 2025 Dec; Vol. 26 (12), pp. 1598-1611.

Způsob vydávání: Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Multicenter Study; Comparative Study

Informace o časopise: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE

Výrazy ze slovníku MeSH: Antibodies, Monoclonal, Humanized*/administration & dosage , Antibodies, Monoclonal, Humanized*/adverse effects , Antibodies, Monoclonal, Humanized*/therapeutic use , Sorafenib*/administration & dosage , Sorafenib*/adverse effects , Sorafenib*/therapeutic use , Liver Neoplasms*/drug therapy , Liver Neoplasms*/pathology , Liver Neoplasms*/mortality , Carcinoma, Hepatocellular*/drug therapy , Carcinoma, Hepatocellular*/pathology , Carcinoma, Hepatocellular*/mortality , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects, Humans ; Male ; Female ; Middle Aged ; Aged ; Adult ; Progression-Free Survival

Lasiodin sensitizes hepatocellular carcinoma cancer to sorafenib via SNARE complex disruption.

Autoři: Lian M Zhang Y Huang J a další

Zdroj: Phytomedicine : international journal of phytotherapy and phytopharmacology [Phytomedicine] 2025 Dec; Vol. 149, pp. 157603. Date of Electronic Publication: 2025 Nov 24.

Způsob vydávání: Journal Article

Informace o časopise: Publisher: Urban & Fischer Verlag Country of Publication: Germany NLM ID: 9438794 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1618-095X (Electronic) Linking ISSN: 09447113 NLM ISO Abbreviation: Phytomedicine Subsets: MEDLINE

Výrazy ze slovníku MeSH: Sorafenib*/pharmacology , Carcinoma, Hepatocellular*/drug therapy , Carcinoma, Hepatocellular*/metabolism , Liver Neoplasms*/drug therapy , Diterpenes*/pharmacology, Humans ; Animals ; Autophagy/drug effects ; Apoptosis/drug effects ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Mice ; Mice, Nude ; Xenograft Model Antitumor Assays ; Mice, Inbred BALB C ; Antineoplastic Agents/pharmacology ; Male ; Hep G2 Cells